P2Y₁₂ inhibitors

Summary

The P2Y₁₂ receptor has proven to be a key target in the prevention of complications associated with atherosclerotic vascular disease especially in the context of acute coronary syndrome and percutaneous coronary intervention in addition to aspirin. Three generationsof thienopyridines, ticlopidine, clopidogrel, and prasugrel have proven efficacy in the prevention of ischemic vascular events but with increased bleeding. The concept of individualized tailored therapy has recently emerged with the discovery of the diminished effect of some thienopyridine among carriers of the loss-of-function cytochrome (CYP) P4502C19*2 variant. Non-thienopyridine P2Y₁₂ antagonists have also recently demonstrated that these benefits are not limited to one class of agents or may be generalizable to reversible antagonists of this receptor. Future rational use of these agents will require attention to disease and patient features to strike the optimal balance of benefit to risk.

Keywords

P2Y₁₂ receptors - thienopyridines - platelet - thrombosis - acute coronary syndrome

• References

• 1 Born Gv. Adenosine diphosphate as a mediator of platelet aggregation in vivo: An editorial view. Circulation 1985; 72: 741-746.
• 2 Maffrand Jp, Bernat A, Delebassée D. et al. ADP plays a key role in thrombogenesis in rats. Thromb Haemost 1988; 59: 225-230.
• 3 Gachet C. Regulation of platelet functions by P2 receptors. Ann Rev Pharmacol Toxicol 2006; 46: 277-300.
• 4 Gachet C, Hechler B. The platelet P2 receptors in thrombosis. Semin Thromb Haemost 2005; 31: 162-167.
• 5 Hechler B, Nonne C, Roh EJ. et al. Mrs2500 [2-IodoN6-methyl-(N)-methanocarba-2‘-deoxyadeno-sine-3‘,5‘-bisphosphate], a potent, selective, and stable antagonist of the platelet P2y1 receptor with strong antithrombotic activity in mice. J Pharmacol Exp Ther 2006; 316: 556-563.
• 6 Leon C, Freund M, Ravanat C. et al. Key role of the P2y(1) receptor in tissue factor-induced thrombin-dependent acute thromboembolism: Studies in P2y(1)-knockout mice and mice treated with a P2y(1) antagonist. Circulation 2001; 103: 718-723.
• 7 Léon C, Hechler B, Freund M. et al. Defective platelet aggregation and increased resistance to thrombosis in purinergic P2y(1) receptor-null mice. J Clin Invest 1999; 104: 1731-1737.
• 8 Hechler B, Lenain N, Marchese P. et al. A role of the fast ATP-gated P2x1 cation channel in thrombosis of small arteries in vivo. J Exp Med 2003; 198: 661-667.
• 9 Hollopeter G, Jantzen Hm, Vincent D. et al. Identification of the platelet ADP receptor targeted by anti-thrombotic drugs. Nature 2001; 409: 202-207.
• 10 Zhang Fl, Luo L, Gustafson E. et al. ADP is the cog-nate ligand for the orphan G protein-coupled receptor Sp1999. J Biol Chem 2001; 276: 8608-8615.
• 11 Gachet C. ADP receptors of platelets and their inhibition. Thromb Haemost 2001; 86: 222-232.
• 12 Ohlmann P, Laugwitz Kl, Nurnberg B. et al. The human platelet ADP receptor activates Gi2 proteins. Biochem J 1995; 312: 775-779.
• 13 Haslam Rj. Interactions of the pharmacological receptors of blood platelets with adenylate cyclase. Ser Haematol 1973; 6: 333-350.
• 14 Savi P, Pflieger Am, Herbert Jm. CAMP is not an important messenger for ADP-induced platelet aggregation. Blood Coagul Fibrinolysis 1996; 7: 249-252.
• 15 Horstrup K, Jablonka B, Honig-Liedl P. et al. Phosphorylation of focal adhesion vasodilator-stimulated phosphoprotein at Ser157 in intact human platelets correlates with fibrinogen receptor inhibition. Eur J Biochem 1994; 225: 21-27.
• 16 Hauser W, Knobeloch Kp, Eigenthaler M. et al. Megakaryocyte hyperplasia and enhanced agonist-induced platelet activation in vasodilator-stimulated phosphoprotein knockout mice. Proc Natl Acad Sci USA 1999; 96: 8120-8125.
• 17 Waldmann R, Nieberding M, Walter U. Vasodilator-stimulated protein phosphorylation in platelets is mediated by cAMP- and cGMP-dependent protein kinases. Eur J Biochem 1987; 167: 441-448.
• 18 Schwarz Ur, Geiger J, Walter U, Eigenthaler M. Flow cytometry analysis of intracellular Vasp phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets. Definition and detection of ticlopidine/ clopidogrel effects. Thromb Haemost 1999; 82: 1145-1152.
• 19 Aleil B, Ravanat C, Cazenave Jp. et al. Flow cytometric analysis of intraplatelet Vasp phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 2005; 3: 85-92.
• 20 Trumel C, Payrastre B, Plantavid M. et al. A key role of adenosine diphosphate in the irreversible platelet aggregation induced by the Par1-activating peptide through the late activation of phosphoinositide 3-kinase. Blood 1999; 94: 4156-4165.
• 21 Kauffenstein G, Bergmeier W, Eckly A. et al. The P2y(12) receptor induces platelet aggregation through weak activation of the alpha(IIb)beta(3) integrin – a phosphoinositide 3-kinase-dependent mechanism. FEBS Lett 2001; 505: 281-290.
• 22 Lova P, Paganini S, Sinigaglia F. et al. A Gi-dependent pathway is required for activation of the small GTPase Rap1b in human platelets. J Biol Chem 2002; 277: 12009-12015.
• 23 Lova P, Paganini S, Hirsch E. et al. A selective role for phosphatidylinositol 3,4,5-trisphosphate in the Gi-dependent activation of platelet Rap1b. J Biol Chem 2003; 278: 131-138.
• 24 Woulfe D, Jiang H, Mortensen R. et al. Activation of Rap1b by G(I) family members in platelets. J Biol Chem 2002; 277: 23382-23390.
• 25 Larson Mk, Chen H, Kahn Ml. et al. Identification of P2y12-dependent and -independent mechanisms of glycoprotein VI-mediated Rap1 activation in platelets. Blood 2003; 101: 1409-1415.
• 26 Hechler B, Eckly A, Ohlmann P. et al. The P2y1 receptor, necessary but not sufficient to support full ADP-induced platelet aggregation, is not the target of the drug clopidogrel. Br J Haematol 1998; 103: 858-866.
• 27 Savi P, Beauverger P, Labouret C. et al. Role of P2y1 purinoceptor in ADP-induced platelet activation. FEBS Lett 1998; 422: 291-295.
• 28 Nieswandt B, Schulte V, Zywietz A. et al. Costimulation of Gi- and G12/G13-mediated signaling pathways induces integrin Alpha IIbbeta 3 activation in platelets. J Biol Chem 2002; 277: 39493-39498.
• 29 Dorsam Rt, Kim S, Jin J, Kunapuli Sp. Coordinated signaling through both G12/13 and G(I) pathways is sufficient to activate GpIIb/IIIa in human platelets. J Biol Chem 2002; 277: 47588-47595.
• 30 Polgar J, Eichler P, Greinacher A, Clemetson Kj. Adenosine diphosphate (ADP) and ADP receptor play a major role in platelet activation/aggregation induced by sera from heparin-induced thrombo -cytopenia patients. Blood 1998; 91: 549-554.
• 31 Gratacap Mp, Herault Jp, Viala C. et al. FcgammarIIa requires a Gi-dependent pathway for an efficient stimulation of phosphoinositide 3-kinase, calcium mobilization, and platelet aggregation. Blood 2000; 96: 3439-3446.
• 32 Saci A, Pain S, Rendu F, Bachelot-Loza C. Fc receptor-mediated platelet activation is dependent on phosphatidylinositol 3-kinase activation and involves P120(Cbl). J Biol Chem 1999; 274: 1898-1904.
• 33 Gratacap Mp, Payrastre B, Viala C. et al. Phosphatidylinositol 3,4,5-trisphosphate-dependent stimulation of phospholipase C-gamma2 is an early key event in FcgammarIIa-mediated activation of human platelets. J Biol Chem 1998; 273: 24314-24321.
• 34 Chacko Gw, Brandt Jt, Coggeshall Km, Anderson Cl. Phosphoinositide 3-kinase and P72syk non -covalently associate with the low affinity Fc gamma receptor on human platelets through an immuno -receptor tyrosine-based activation motif. Reconstitution with synthetic phosphopeptides. J Biol Chem 1996; 271: 10775-10781.
• 35 Nieswandt B, Bergmeier W, Eckly A. et al. Evidence for cross-talk between glycoprotein VI and Gi-coupled receptors during collagen-induced platelet aggregation. Blood 2001; 97: 3829-3835.
• 36 Cattaneo M, Lombardi R, Zighetti Ml. et al. Deficiency of (33p)2mes-ADP binding sites on platelets with secretion defect, normal granule stores and normal thromboxane A2 production. Evidence that ADP potentiates platelet secretion independently of the formation of large platelet aggregates and thromboxane A2 production. Thromb Haemost 1997; 77: 986-990.
• 37 Cattaneo M, Lecchi A, Lombardi R. et al. Platelets from a patient heterozygous for the defect of P2cyc receptors for ADP have a secretion defect despite normal thromboxane A2 production and normal granule stores: Further evidence that some cases of platelet ‘primary secretion defect’ are heterozygous for a defect of P2cyc receptors. Arterioscler Thromb Vasc Biol 2000; 20: E101-E106.
• 38 Léon C, Freund M, Ravanat C. et al. Key role of the P2y(1) receptor in tissue factor-induced thrombin-dependent acute thromboembolism: Studies in P2y(1)-knockout mice and mice treated with a P2y(1) antagonist. Circulation 2001; 103: 718-723.
• 39 Léon C, Ravanat C, Freund M. et al. Differential involvement of the P2y1 and P2y12 receptors in platelet procoagulant activity. Arterioscler Thromb Vasc Biol 2003; 23: 1941-1947.
• 40 Dorsam Rt, Tuluc M, Kunapuli Sp. Role of protease-activated and ADP receptor subtypes in thrombin generation on human platelets. J Thromb Haemost 2004; 2: 804-812.
• 41 Storey Rf, Sanderson Hm, White Ae. et al. The central role of the P(2t) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Br J Haematol 2000; 110: 925-934.
• 42 Cattaneo M, Lecchi A, Randi Am. et al. Identification of a new congenital defect of platelet function characterized by severe impairment of platelet responses to adenosine diphosphate. Blood 1992; 80: 2787-2796.
• 43 Cattaneo M, Gachet C. ADP receptors and clinical bleeding disorders. Arterioscler Thromb Vasc Biol 1999; 19: 2281-2285.
• 44 Cattaneo M, Zighetti Ml, Lombardi R. et al. Molecular bases of defective signal transduction in the platelet P2y12 receptor of a patient with congenital bleeding. Proc Natl Acad Sci USA 2003; 100: 1978-1983.
• 45 Cattaneo M. The P2 receptors and congenital platelet function defects. Semin Thromb Haemost 2005; 31: 168-173.
• 46 Andre P, Delaney Sm, Larocca T. et al. P2Y₁₂ regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries. J Clin Invest 2003; 112: 398-406.
• 47 Andre P, Larocca T, Delaney Sm. et al. Anticoagulants (thrombin inhibitors) and aspirin synergize with P2y12 receptor antagonism in thrombosis. Circulation 2003; 108: 2697-2703.
• 48 Savi P, Herbert Jm. Clopidogrel and ticlopidine: P2y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost 2005; 31: 174-183.
• 49 Gent M, Blakely Ja, Easton Jd. et al. The Canadian American Ticlopidine Study (Cats) in Thromboembolic Stroke. Lancet. 1989; 1: 1215-1220.
• 50 Hass Wk, Easton Jd, Adams Hp. et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med 1990; 322: 404-405.
• 51 Bertrand Me, Rupprecht Hj, Urban P, Gershlick Ah. Classics Investigators.. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: The Clopidogrel Aspirin Stent International Cooperative Study (Classics). Circulation 2000; 102: 624-629.
• 52 Smith Jr Sc, Allen J, Blair Sn. et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 Update. Circulation 2006; 113: 2363-2372.
• 53 Steinhubl Sr, Berger S, Mann Jt. et al. for the Credo Investigators. Early and Sustained Dual Oral Anti-platelet Therapy Following Percutaneous Coronary Intervention. JAMA 2002; 288: 2411.
• 54 The Cure Investigators.. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without St-segment elevation. N Eng J Med 2001; 345: 494-502.
• 55 Snoep SD, Hovens MMC, Eikenboom JCJ. et al. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: A systematic review and meta-analysis. Am Heart J 2007; 154: 220-231.
• 56 Montalescot G, Sideris G, Meuleman C. et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: The Albion (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) Trial. J Am Coll Cardiol 2006; 48: 931-938.
• 57 Niitsu Y, Jakubowski Ja, Sugidachi A, Asai F. Pharmacology of Cs-747 (prasugrel, Ly640315), a novel, potent antiplatelet agent with in vivo P2y12 receptor antagonist activity. Semin Thromb Hemost 2005; 31: 184-194.
• 58 Jakubowski Ja, Matsushima N, Asai F. et al. A multiple dose study of prasugrel (Cs-747), a novel thienopyridine P2y12 inhibitor, compared with clopidogrel in healthy humans. Br J Clin Pharmacol 2007; 63: 421-330.
• 59 Jernberg T, Payne Cd, Winters Kj. et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006; 27: 1166-1173.
• 60 Sugidachi A, Ogawa T, Kurihara A. et al. The greater in vivo antiplatelet effects of prasugrel compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to clopidogrel‘s active metabolite. J Thromb Haemost 2007; 5: 1545-1551.
• 61 Wiviott Sd, Trenk D, Frelinger Al. et al. for the principle-TIMI 44 Investigators. Prasugrel compared to high loading and maintenance dose clopidogrel in patients with planned percutaneous coronary intervention. Circulation 2007; 116: 2923-2932.
• 62 Wiviott Sd, Antman Em, Winters Kj. et al. Jumbo-TIMI 26 Investigators.. Randomized comparison of prasugrel (Cs-747, Ly640315), a novel thienopyri-dine P2y12 antagonist, with clopidogrel in percutaneous coronary intervention: Results of the Joint Utilization of Medications to Block Platelets Optimally (Jumbo)-TIMI 26 Trial. Circulation 2005; 111: 3366-3373.
• 63 Wiviott Sd, Braunwald E, Mccabe Ch. et al. The Triton- TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
• 64 Wiviott Sd, Braunwald E, Mccabe Ch. et al. TritonTIMI 38 Investigators. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the Triton-TIMI 38 Trial: A subanalysis of a randomised trial. Lancet 2008; 371 9621 1353-1363.
• 65 Montalescot G, Wiviott Sd, Braunwald E. et al. Triton TIMI 38 Investigators. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (Triton-TIMI 38): Double-blind, randomised controlled trial. Lancet 2009; 373 9665 723-731.
• 66 Peters G, Robbie G. Single-dose pharmacokinetics and pharmacodynamics of Azd6140-an oral reversible ADP receptor antagonist. Haematologica 2004; 989 (Suppl. 07) 14.
• 67 Husted S, Emanuelsson H, Heptinstall S. et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2y12 antagonist Azd6140 with aspirin in patients with atherosclerosis: A double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006; 27: 1038-1047.
• 68 Wallentin L, Becker Rc, Budaj A. et al. The Plato Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009 361: 10.1056/NEJMoa0904327.
• 69 Collet Jp, Hulot Js, Pena A. et al. Cytochrome P450 2c19 polymorphism in young patients treated with clopidogrel after myocardial infarction: A cohort study. Lancet 2009; 373: 309-317.
• 70 Gurbel Pa, Bliden Kp, Ryan K. et al. Influence of Cyp2c19 polymorphism on antiplatelet effects of clopidogrel and long-term recurrent ischemic event occurrence. J Am Coll Cardiol Intervention 2009; 10 (Suppl. 01) I2 2404.
• 71 Mega Jl, Close Sl, Wiviott Sd. et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-362.
• 72 Simon T, Verstuyft C, Mary-Krause M. et al. for the French Registry of Acute St-Elevation and Non–ST-Elevation Myocardial Infarction (Fast-Mi) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360: 363-375.
• 73 Pena A, Collet Jp, Hulot Js. et al. Can we override clopidogrel resistance?. Circulation 2009; 119: 2854-2857.